Cumberland Pharmaceuticals, Pernix Therapeutics Partner to Promote H. Pylori Treatment

Cumberland Pharmaceuticals and Pernix Therapeutics have come to an agreement to distribute Omeclamox-Pak in the United States.

Advertisement

Omeclamox-Pak is an FDA-approved prescription drug that combines several drug therapies for treatment of Helicobacter pylori infection and duodenal ulcer disease.

Cumberland will promote the drug to its gastroenterologists, and Pernix will promote the produce to its primary care physicians.

More Articles on Gastroenterology:
gMed Announcces gInsights Business & Clinical Intelligence Platform
Stay Competitive: 5 Enhancements for GI/Endoscopy Groups
gGastro EHR System Receives Full EHR Certification

Advertisement

Next Up in GI & Endoscopy

  • General gastroenterologists earn an average base salary of $526,273 — more than $218,000 higher than their pediatric counterparts, who report…

  • The MUSC Shawn Jenkins Children’s Hospital in Charleston, S.C., has launched the MUSC Advanced Pediatric Endoscopy Program and Pancreas Center. …

Advertisement

Comments are closed.